BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22383632)

  • 1. A new neutral-pH low-GDP peritoneal dialysis fluid.
    Himmele R; Jensen L; Fenn D; Ho CH; Sawin DA; Diaz-Buxo JA
    Perit Dial Int; 2012; 32(4):444-52. PubMed ID: 22383632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pH-neutral peritoneal dialysis solution, low in glucose degradation products, in a double-chamber bag.
    Diaz-Buxo J; Clark SC; Ho CH; Jensen LE
    Adv Perit Dial; 2010; 26():28-32. PubMed ID: 21348375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
    Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
    Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
    Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
    Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats.
    Musi B; Carlsson O; Rippe A; Wieslander A; Rippe B
    Perit Dial Int; 1998; 18(3):303-10. PubMed ID: 9663895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dual-chambered bag.
    Lage C; Pischetsrieder M; Aufricht C; Jörres A; Schilling H; Passlick-Deetjen J
    Perit Dial Int; 2000; 20 Suppl 5():S28-32. PubMed ID: 11229609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of peritoneal ultrafiltration with peritoneal dialysis solution buffered with bicarbonate/lactate mixture.
    Simonsen O; Sterner G; Carlsson O; Wieslander A; Rippe B
    Perit Dial Int; 2006; 26(3):353-9. PubMed ID: 16722029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to avoid glucose degradation products in peritoneal dialysis fluids.
    Erixon M; Wieslander A; Lindén T; Carlsson O; Forsbäck G; Svensson E; Jönsson JA; Kjellstrand P
    Perit Dial Int; 2006; 26(4):490-7. PubMed ID: 16881345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats.
    Wieczorowska-Tobis K; Polubinska A; Schaub TP; Schilling H; Wisniewska J; Witowski J; Passlick-Deetjen J; Breborowicz A
    Perit Dial Int; 2001; 21 Suppl 3():S108-13. PubMed ID: 11887803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se.
    Witowski J; Bender TO; Wisniewska-Elnur J; Ksiazek K; Passlick-Deetjen J; Breborowicz A; Jörres A
    Perit Dial Int; 2003; 23(4):381-90. PubMed ID: 12968847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
    Lai KN; Lam MF; Leung JC; Chan LY; Lam CW; Chan IH; Chan HW; Li CS; Wong SS; Ho YW; Cheuk A; Tong MK; Tang SC
    Perit Dial Int; 2012; 32(3):280-91. PubMed ID: 22045098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of peritoneal dialysis in the first weeks after catheter insertion: A comparison of a neutral-pH, low-GDP PD fluid and a conventional PD fluid
.
    Farhat K; van Ittersum FJ; Ter Wee PM; Paauw NJ; Beelen RHJ; Douma CE
    Clin Nephrol; 2018 Feb; 89(2):75-82. PubMed ID: 28992851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products.
    Wieczorowska-Tobis K; Brelinska R; Witowski J; Passlick-Deetjen J; Schaub TP; Schilling H; Breborowicz A
    Perit Dial Int; 2004; 24(1):48-57. PubMed ID: 15104336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
    De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
    Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.
    Sugiyama N; Tawada M; Sun T; Suzuki Y; Kinashi H; Yamaguchi M; Katsuno T; Aten J; Vlahu CA; van Kuppevelt TH; Takei Y; Ishimoto T; Maruyama S; Mizuno M; Ito Y
    Clin Exp Nephrol; 2021 Sep; 25(9):1035-1046. PubMed ID: 33999275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
    Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
    Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats.
    Ikehara O; Nishimura H; Naito T; Higuchi C; Sanaka T
    Nephron Exp Nephrol; 2005; 100(1):e30-9. PubMed ID: 15731567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.